Literature DB >> 26870272

Solitary recurrence of castration-resistant prostate cancer with low or undetectable levels of prostate specific antigen salvaged with local ablative radiation therapy: A case report.

Chiachien Jake Wang1, James Ying1, Payal Kapur2, Bryan Wohlfeld3, Claus Roehrborn4, Dong W Nathan Kim5.   

Abstract

Prostate cancer recurrences are usually first detected by increased levels of prostate specific antigen (PSA), and systemic therapy is often initiated if distant metastasis is confirmed. However, low or nearly undetectable levels of PSA in the modern era of ultrasensitive PSA assay may be difficult to interpret in patients with a history of prostate cancer. Deciding whether to initiate additional systemic therapy in limited indolent metastatic disease while balancing the quality of life of the patient and ensuring the oncologic control of the disease may be challenging. In the present study, the case of a biopsy-confirmed solitary spine recurrence of prostate cancer with nearly undetectable but persistent levels of PSA (0.05 ng/ml) is reported. Treatment of the recurrence with local ablative radiotherapy improved the pain experienced by the patient, and reduced his levels of PSA to undetectable limits (<0.05 ng/ml). Repeated imaging analysis, PSA assay and clinical assessment demonstrated durable control of the disease without the requirement for additional systemic treatments. The present case highlighted the importance of initiating appropriate work-up according to the clinical scenario. Local treatment for solitary or oligometastatic recurrence of prostate cancer may enhance the effectiveness of current therapeutic strategies and benefit certain patients.

Entities:  

Keywords:  oligometastasis; prostate cancer; salvage therapy; stereotactic body radiotherapy; undetectable prostate specific antigen

Year:  2015        PMID: 26870272      PMCID: PMC4727102          DOI: 10.3892/ol.2015.3940

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  29 in total

1.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Authors:  Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

2.  Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level.

Authors:  B D Leibman; O Dillioglugil; T M Wheeler; P T Scardino
Journal:  Cancer       Date:  1995-12-15       Impact factor: 6.860

3.  Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.

Authors:  William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio
Journal:  J Natl Cancer Inst       Date:  2005-06-01       Impact factor: 13.506

Review 4.  Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice.

Authors:  Robert D Timmerman; Joseph Herman; L Chinsoo Cho
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 5.  Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.

Authors:  Judd W Moul; Nancy Dawson
Journal:  Cancer Invest       Date:  2012-01       Impact factor: 2.176

Review 6.  Stereotactic body radiotherapy treatment of extracranial metastases.

Authors:  Joseph K Salama; John P Kirkpatrick; Fang-Fang Yin
Journal:  Nat Rev Clin Oncol       Date:  2012-09-25       Impact factor: 66.675

Review 7.  Castration-resistant prostate cancer: latest evidence and therapeutic implications.

Authors:  Daniel L Suzman; Emmanuel S Antonarakis
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

8.  The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies.

Authors:  M G Oefelein; N Smith; M Carter; D Dalton; A Schaeffer
Journal:  J Urol       Date:  1995-12       Impact factor: 7.450

9.  Prostate specific antigen and gleason grade: an immunohistochemical study of prostate cancer.

Authors:  M Aihara; R M Lebovitz; T M Wheeler; B M Kinner; M Ohori; P T Scardino
Journal:  J Urol       Date:  1994-06       Impact factor: 7.450

10.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.

Authors:  Padraig Warde; Malcolm Mason; Keyue Ding; Peter Kirkbride; Michael Brundage; Richard Cowan; Mary Gospodarowicz; Karen Sanders; Edmund Kostashuk; Greg Swanson; Jim Barber; Andrea Hiltz; Mahesh K B Parmar; Jinka Sathya; John Anderson; Charles Hayter; John Hetherington; Matthew R Sydes; Wendy Parulekar
Journal:  Lancet       Date:  2011-11-02       Impact factor: 79.321

View more
  1 in total

Review 1.  Oligometastatic prostate cancer: Reality or figment of imagination?

Authors:  Corey C Foster; Ralph R Weichselbaum; Sean P Pitroda
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.